L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study

被引：0

作者：

Duell, J. ^{[1
]}

Gonzalez Barca, E. ^{[2
]}

Liberati, A. M. ^{[3
]}

Salles, G. ^{[4
]}

Gaidano, G. ^{[5
]}

Jurczak, W. ^{[6
]}

Nagy, Z. ^{[7
]}

Papajlk, T. ^{[8
,9
]}

Andre, M. ^{[10
]}

Zinzani, P. L. ^{[11
]}

Kalakonda, N. ^{[12
]}

Ambarkhane, S. ^{[13
]}

Weirather, J. ^{[13
]}

Maddocks, K. ^{[14
]}

Dreyling, M. ^{[15
]}

机构：

[1] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] IDIBELL, Dept Hematol, Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain

[3] Azienda Osped Santa Maria, SC Oncoematol, Terni, Italy

[4] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Hematol, Pierre Benite, France

[5] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[6] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[7] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary

[8] Palacky Univ Olomouc, Olomouc, Czech Republic

[9] Univ Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic

[10] Catholic Univ Louvain, CHU UCL Namur, Dept Hematol, Yvoir, Belgium

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England

[13] MorphoSys AG, Planegg, Germany

[14] Ohio State Univ, Dept Internal Med, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA

[15] LMU, Univ Hosp, Med Klin & Poliklin 3, Munich, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P260

引用

页码：68 / 68

页数：1

共 50 条

[1] L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL)-A SINGLE-ARM PHASE II STUDY
Maddocks, K.
Gonzalez Barca, E.
Jurczak, W.
Liberati, A. M.
Duell, J.
Nagy, Z.
Papaj-K, T.
Andre, M.
Kalakonda, N.
Dreyling, M.
Zinzani, P. L.
Ambarkhane, S.
Weirather, J.
Salles, G.
HAEMATOLOGICA, 2017, 102 : 174 - 174
[2] L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)-A single-arm phase II study.
Maddocks, Kami J.
Barca, Eva Gonzalez
Jurczak, Wojciech
Liberati, Anna Marina
Duell, Johannes
Nagy, Zsolt
Papajik, Tomas
Andre, Marc
Kalakonda, Nagesh
Dreyling, Martin H.
Zinzani, Pier Luigi
Ambarkhane, Sumeet Vijay
Weirather, Johannes
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[3] Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
Salles, Gilles Andre
Duell, Johannes
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Andre, Marc
Kalakonda, Nagesh
Dreyling, Martin
Zinzani, Pier Luigi
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet
Maddocks, Kami J.
BLOOD, 2018, 132
[4] Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
Salles, Gilles Andre
Duell, Johannes
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
Nagy, Zsolt
Papajik, Tomas
Gaidano, Gianluca
Andre, Marc
Kalakonda, Nagesh
Dreyling, Martin
Zinzani, Pier Luigi
Ambarkhane, Sumeet
Weirather, Johannes
Dirnberger-Hertweck, Maren
Maddocks, Kami J.
BLOOD, 2017, 130
[5] Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Dull, Johannes
Maddocks, Kami J.
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
Obr, Ales
Gaidano, Gianluca
Abrisqueta, Pau
Andre, Marc
Dreyling, Martin H.
Menne, Tobias
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet Vijay
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Update of the single-arm phase II L-MIND study of MOR208+lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.
Maddocks, Kami J.
Duell, Johannes
Barca, Eva Gonzalez
Jurczak, Wojciech
Liberati, Anna Marina
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Andre, Marc
Kalakonda, Nagesh
Dreyling, Martin H.
Zinzani, Pier Luigi
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet Vijay
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Duell, Johannes
Maddocks, Kami J.
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
de Vos, Sven
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Abrisqueta, Pau
Andre, Marc
Dreyling, Martin
Menne, Tobias F.
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet
Salles, Gilles A.
BLOOD, 2019, 134
[8] Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study
Gonzalez-Barca, Eva
Duell, Johannes
Cavallo, Federica
Sancho, Juan-Manuel
Nagy, Zsolt
Abrisqueta, Pau
Panizo, Carlos
Augustin, Marinela
Weirather, Johannes
Ambarkhane, Sumeet
Maddocks, Kami J.
Kalakonda, Nagesh
Salles, Gilles
BLOOD, 2020, 136
[9] Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Maddocks, Kami J.
Duell, Johannes
Gonzalez-Barca, Eva
Jurczak, Wojciech
Liberati, Anna Marina
de Vos, Sven
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Abrisqueta, Pau
Andre, Marc
Dreyling, Martin
Menne, Tobias F.
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet
Salles, Gilles
BLOOD, 2020, 136
[10] Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Duell, J.
Gonzalez-Barca, E.
Augustin, M.
Jurczak, W.
Liberati, A. M.
de Vos, S.
Nagy, Z.
Obr, A.
Gaidano, G.
Abrisqueta, P.
Kalakonda, N.
Andre, M.
Menne, T.
Tournilhac, O.
Waltl, E. E.
Dirnberger-Hertweck, M.
Weirather, J.
Maddocks, K. J.
Ambarkhane, S.
Dreyling, M.
Salles, G.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 63 - 64

← 1 2 3 4 5 →